New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 26, 2014
08:31 EDTBPTHBio-Path Holdings names Ulrich Mueller as COO
Bio-Path Holdings announced that Dr. Ulrich W. Mueller has joined the company as COO. Dr. Mueller will be responsible for the company’s drug development, licensing and intellectual property activities, including managing the company’s clinical trials, pre-clinical and research and development efforts. Mueller was previously a Vice President at the Fred Hutchinson Center Research Center.
News For BPTH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 22, 2014
08:33 EDTBPTHBio-Path Holdings to initiate development of Liposomal Bcl-2
Bio-Path Holdings announced that it has initiated development of Liposomal Bcl-2 as a treatment for follicular lymphoma. Bio-Path has a completed preclinical package of toxicity, tissue distribution, pharmacokinetics and efficacy studies. The company plans to file an Investigational New Drug application in the first half of 2015. Bio-Path’s L-Bcl-2 demonstrated excellent toxicity and efficacy in preclinical studies. The in vivo studies of follicular lymphoma in SCID mice demonstrated a 60 percent survival rate, with the treated mice remaining alive while continuing to receive on-going treatment with the compound. The company expects that the Phase I clinical trial design will use a standard 3+3 dose escalation design, with 50 percent dose escalation with each round. The company anticipates that the favorable toxicity profile of its lead drug candidate Liposomal Grb-2, currently in clinical trials, will allow it to start this Phase I clinical trial at a higher dose. On this basis, the company is planning a Phase I clinical trial for Liposomal Bcl-2 that will require five cohorts and only 15 patients.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use